The authors speculate that this may be associated with changes in levels of endogenous PPARα ligands in CF, but that treatment with synthetic PPARα ligands may increase receptor expression and activity to minimise the immune response [41]. The gene discussed is PPARA; the disease is cystic fibrosis.